Drugs / mRNA-1944
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03829384 | Jan 2019 → Jun 2021 | chikungunya | ModernaTX, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2020-09-17 | ModernaTX, Inc. | Results Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day q4web.com ↗
Positive data from additional cohorts of Phase 1 study evaluating escalating doses of antibody against the chikungunya virus (mRNA-1944) administered via intravenous infusion in healthy adults |
| 2019-11-06 | ModernaTX, Inc. | Results Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results q4web.com ↗
Positive interim results announced from Phase 1 chikungunya antibody (mRNA-1944) study |
| 2019-09-12 | ModernaTX, Inc. | Results Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) q4web.com ↗
At all three dose levels, the administration of mRNA-1944 led to detectable levels of CHKV-24 antibody in all participants, ranging from 1 µg/mL to 14 µg/mL. |
| 2019-09-12 | ModernaTX, Inc. | Results Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials q4web.com ↗
The Company also announced positive Phase 1 data for mRNA-1944 (mRNA encoding for antibody against chikungunya virus) today. |
| 2019-05-17 | ModernaTX, Inc. | Results Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program q4web.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-09-17 | ModernaTX, Inc. | Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day q4web.com ↗ |
| 2019-11-06 | ModernaTX, Inc. | Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results q4web.com ↗ |
| 2019-09-12 | ModernaTX, Inc. | Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) q4web.com ↗ |
| 2019-09-12 | ModernaTX, Inc. | Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials q4web.com ↗ |
| 2019-05-17 | ModernaTX, Inc. | Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program q4web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03829384 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody” PMID 34887572 ↗ Dec 2021 |
| Route | Intravenous | “mRNA-1944 administered via intravenous infusion” PMID 34887572 ↗ Dec 2021 |